Dr. Bhalla is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5323 Harry Hines Boulevard
Dallas, TX 75390Phone+1 214-645-4673Fax+1 214-648-1955
Education & Training
Icahn School of Medicine at Mount SinaiFellowship, Hematology and Medical Oncology, 2018 - 2021- Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 2015 - 2018
University of Florida College of MedicineClass of 2015
Certifications & Licensure
TX State Medical License 2021 - 2026
NY State Medical License 2017 - 2021- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Phase 2 Trial of Afatinib Plus Prednisone for Advanced Squamous NSCLC Start of enrollment: 2021 Aug 04
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- 704 citationsPD-L1 as a biomarker of response to immune-checkpoint inhibitorsDeborah B. Doroshow, Sheena Bhalla, Mary Beth Beasley, Lynette M. Sholl, Keith M. Kerr
Nature Reviews. Clinical Oncology. 2021-02-12 - 26 citationsLong-term follow-up for efficacy and safety of treatment of retinitis pigmentosa with valproic acidSheena Bhalla, Deval D. Joshi, Shaminder S. Bhullar, Daniel Kasuga, Yeonhee Park
The British Journal of Ophthalmology. 2013-07-01 - 48 citationsCancer Care Disparities during the COVID-19 Pandemic: COVID-19 and Cancer Outcomes Study.Andrew Schmidt, Ziad Bakouny, Sheena Bhalla, John A. Steinharter, Douglas Tremblay
Cancer Cell. 2020-12-14
Press Mentions
AI Tool May Predict Lung Cancer with 94% Accuracy with 1 Year of ScreeningJanuary 20th, 2023
Routine COVID-19 Screening Unnecessary for Cancer OutpatientsFebruary 19th, 2021
PD-L1 as a Biomarker of Response to Immune-Checkpoint InhibitorsFebruary 12th, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
